Identification of aurora kinase A as an unfavorable prognostic factor and potential treatment target for metastatic gastrointestinal stromal tumors
Although imatinib mesylate (IM) has revolutionized the management of gastrointestinal stromal tumors (GISTs), drug resistance remains a challenge. Previous studies have shown that the expression of aurora kinase A (AURKA) predicts recurrence in patients with primary, surgically resected GISTs. The c...
Main Authors: | Yeh, Chun-Nan, Yen, Chueh-Chuan, Chen, Yen-Yang, Cheng, Chi-Tung, Huang, Shih-Chiang, Chang, Ting-Wei, Yao, Fang-Yi, Lin, Yung-Chan, Wen, Yao-Shan, Chiang, Kun-Chun, Chen, Jen-Shi, Yeh, Ta-Sen, Tzeng, Cheng-Hwai, Chao, Ta-Chung, Fletcher, Jonathan A. |
---|---|
Format: | Online |
Language: | English |
Published: |
Impact Journals LLC
2014
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4147307/ |
Similar Items
-
Fractioned Dose Regimen of Sunitinib for Patients with Gastrointestinal Stromal Tumor: A Pharmacokinetic and Treatment Efficacy Study1
by: Chen, Yen-Yang, et al.
Published: (2014) -
Feasibility and Timing of Cytoreduction Surgery in Advanced (Metastatic or Recurrent) Gastrointestinal Stromal Tumors During the Era of Imatinib
by: Chang, Shih-Chun, et al.
Published: (2016) -
Autophagy is involved in endogenous and NVP-AUY922-induced KIT degradation in gastrointestinal stromal tumors
by: Hsueh, Yuan-Shuo, et al.
Published: (2013) -
Peritumoral SPARC expression and patient outcome with resectable intrahepatic cholangiocarcinoma
by: Cheng, Chi-Tung, et al.
Published: (2015) -
Evaluation of prognostic factors and the role of chemotherapy in unfavorable carcinoma of unknown primary site: a 10-year cohort study
by: Chen, Kuo-Wei, et al.
Published: (2012)